- Global Value and Access Therapeutic Head overseeing day-to-day operations of the General Medicines Global Pricing and Access team (in addition to Immunology for 9 months), driving cross-functional collaboration and functional execution for inline and pipeline, reviewing 100+ affiliate pricing exception business cases and 10+ Global Value Dossiers delivered per year. Commercial representative of the Therapeutic Area Governance (TAG).- Enhanced global payer strategies by steering the Access Strategy Leadership Team, centralizing input from Country Access leaders to integrate affiliate experiences for effective local negotiations in the top 10 markets, while actively participating in product strategy development via Global Access Product Teams (GATs).- 50+ successful country negotiations supported including NRDL listing for Evolocumab in China and reimbursement decisions for Romosozumab in UK, Italy, Australia, Canada and Germany. Supporting several reimbursement submissions for partnered or acquired products in areas such as Ashma, ANCA-associated vasculitis (rare disease), osteoporosis and migraine, while representing Amgen in 3 Joint Steering Committees.- Lead the global workstream to quantify IRA impact on pipeline molecules to the US future business (CMS and spill-over to commercial plans) for all 4 therapeutic areas. Sponsored the Artificial Intelligence-AI workstream for Pricing & Market Access.

- Integrated HEOR, Market Access Strategy and Policy functions to establish Sotorasib’s Global Pricing Policy through aligned strategic planning, governance, compliance, functional collaborations, and internal business protocols.- Oversight of other early solid tumor pipeline assets like AMG596 for glioblastoma and AMG650 for triple negative breast cancer (TNBC) and ovarian cancer.- Orchestrated the global and US launch of Sotorasib (oncology) and lead the development of the global pricing policy for US and exUS markets.- Work in partnership with 2 companion diagnostics companies (Guardant and Qiagen) to optimize testing with a comprehensive wrap around strategy in multiple platforms (FDA approved test, NGS, LDTs) to drive testing to 85%+.- Global approval and support to countries in the implementation of Temporary Access Mechanisms in multiple countries, including successfully obtaining cancer drugs fund-CDF approval in the UK, France and China.- Managed a global OPEX budget exceeding $2M per year, maintaining less than 0.5% variance from budget through meticulous tracking, reporting, and agile resource reallocation strategies.

- Commercial and access leader of multidisciplinary team of 40+ professionals, spearheaded negotiations with the Brazilian Ministry of Health and large private health plans.- Exceeded the US$ 200 million sales milestone in 2018 by implementing innovative outcomes-based contracting strategies.- Grew 9% and 12% over the company’s operating plan for 2018 and 2019 respectively, surpassing the ~ US$ 200 million of sales milestone, enabled through implementation of innovative contracting strategies with wholesalers and payers.- Lead the access & commercial execution of the launch of Avelumab to treat Merkel cell carcinoma (MCC), a rare and aggressive skin cancer.- Managed team of commercial key account managers, optimizing relationships with wholesalers and large provider accounts.

- Lead market access and pricing function for oncology and hematology across Latin America.- Developed and implemented innovative pricing & reimbursement launch plans for key products, including Erleada and Darzalex, while enhancing access and volume growth for inline brands such as Imbruvica and Zytiga.

Last position: International Payer Strategy Lead (Director)